Sanofi moves patients out of Ukraine warzone in 'Herculean effort' to preserve MS trials AbbVie's cystic fibrosis long-game doesn't pay off, as Galapagos med fails in triple combo ‘Serious missteps’: All Blue makes case for $773M Zymeworks buyout in wake of flagging stock Sponsored: Using Knowledge Graphs to Drive Drug Discovery Finch's C. diff drug cleared of FDA hold, but loose ends leave timing for phase 3 restart unclear While BMS waits for TYK2 inhibitor’s psoriasis nod, a new path potentially clears in lupus AstraZeneca kicks off work on 1,500-person R&D center in Kendall Square Genocea's Atlas no longer holding up sky, as biotech moves for sell off Biogen CEO's 2021 pay remains level despite Aduhelm tribulations Music to Cochlear's ears: Demant trades Oticon hearing implant business for $120M How to reach Hispanics with healthcare messages? Mine the data first, Klick says Ex-Cerebral executive files lawsuit claiming the startup overprescribed ADHD meds Bristol Myers bags FDA nod for blockbuster-to-be cardio drug Camzyos Chutes & Ladders—Merck loses another top exec, this time to Moderna Fierce Pharma Asia—Astellas’ gene therapy write-off; BeiGene, Novartis’ PD-1 win; Serum Institute’s unused COVID shots Featured Story | By James Waldron Sanofi has moved clinical trial patients out of Ukraine, as European pharma companies scramble to maintain their multiple sclerosis studies in the wake of the conflict brought on by the Russian invasion. read more |
| |
|---|
|
| | Harness the power of eCOA in your next trial Keep patients at the center of care while increasing efficiencies, data integrity and regulatory compliance. IQVIA’s leaders will help you deploy strategic eCOA tools, maximize patient needs and acquire real-time insights that demonstrate results. Learn more. |
Top Stories By Annalee Armstrong AbbVie is discontinuing a cystic fibrosis medicine after an interim analysis revealed that the therapy did nothing when added to a triple-combo regimen, putting a dent in the pharma’s efforts to compete with Vertex’s Trikafta. read more By Nick Paul Taylor Investment firm All Blue Capital has offered Zymeworks a way out of its current troubles. After watching the late-stage biotech’s share price collapse over the past year, All Blue has bid $773 million to take the company private—and torn into perceived leadership failures that contributed to its decline. read more Sponsored By: QIAGEN Digital Insights Biomedical knowledge graphs can power many different application in drug discovery. Learn which key feature you should look for and why. read more By Annalee Armstrong Ten days after Finch Therapeutics let go 20% of its workforce, the winds have changed. The FDA has lifted a clinical hold on the biotech’s donor-derived microbiome drug for Clostridioides difficile, clearing the way for a phase 3 study to proceed—eventually. read more By Max Bayer While Bristol Myers Squibb anxiously awaits an FDA decision on its TYK2 inhibitor med to treat plaque psoriasis, it has hinted that the drug could have a separate life as a lupus therapy. read more By Nick Paul Taylor AstraZeneca is again building in a city called Cambridge. Shortly after completing its late, over-budget R&D center in Cambridge, U.K., the British pharma has begun work across the Atlantic on a facility in Kendall Square that will house its staffers alongside their Alexion colleagues. read more By Annalee Armstrong Just weeks ago, Genocea Biosciences was touting phase 1/2 proof of concept data. Now, the biotech has hired an investment bank to conduct a strategic review and potentially sell off the company entirely or in parts. read more By Fraiser Kansteiner Biogen CEO Michel Vounatsos’ 2021 pay dropped about $1 million from 2020. Still, the helmsman got off light, considering the incredibly rocky rollout of Biogen’s controversial Alzheimer’s disease drug Aduhelm. read more By Andrea Park Oticon Medical’s ears must be burning after parent company Demant struck a deal to divest the implant business in a sale to fellow hearing technology developer Cochlear. read more By Sharon Klahr Coey One in five Americans are Hispanic (with projections of one in four by 2050), so properly serving this community is not only important but also necessary. Klick Heath and cross-cultural research technology company ThinkNow have some data-based ideas about how to do just that. read more By Heather Landi A former executive at Cerebral, a well-funded online mental health startup, claims in a labor lawsuit that the company fired him after he complained about unlawful business practices. read more By Fraiser Kansteiner The FDA on Thursday granted Bristol Myers Squibb’s mavacamten a green light to treat symptomatic obstructive hypertrophic cardiomyopathy. Now christened Camzyos, the drug represents a potential blockbuster addition to BMS’ cardiovascular stable—which needs fresh blood ahead of top-seller Eliquis’ plunge off the patent cliff later this decade. read more By Max Bayer Moderna has tapped Arpa Garay, Merck's chief marketing officer of its human health division, to become chief commercial officer. Novartis brings aboard long-time analyst Gal to guide M&A strategy as it looks to steady the ship. After its once-historic deal with Bristol Myers Squibb cratered, Nektar Therapeutics bid farewell to both its chief medical and commercial officers. read more By Angus Liu Astellas took another big impairment from its gene therapy programs. Novartis and BeiGene's PD-1 inhibitor posted a survival win in esophageal cancer. AstraZeneca's COVID-19 vaccine manufacturing partner Serum Institute of India has halted production. And more. read more Resources Sponsored By: H1 More than 570 clinical trials in Ukraine have been disrupted. Unanticipated disruptions to medical testing and clinical trials impede progress toward new breakthroughs and new therapies that millions of patients around the world hang their hope on. What role do rescue sites play? Sponsored by: United Cargo The United Cargo team has made a commitment to pharmaceutical and medical partners that we are equipped to support their vaccine transportation needs safely and effectively across our expansive global and domestic network. The safety and security of these commodities is our priority, and we are proud to be a trusted partner in these efforts. Download infographic now. Presented By: Springer Nature The journey of drug development in 2021 delivered to your inbox: top 10 AdisInsight drug profiles viewed, new drug profiles released, overview of drug launches, key deals, research trends in 2021 and much more (free of charge). Sponsored by: Blue Matter, strategic consultants in the life sciences What’s in store for the oncology market in 2022 and beyond? This paper looks at 5 trends driving the market. Sponsored by: Thermo Fisher Scientific Learn how to position quality as a central component within your raw material sourcing strategies for the chemicals used throughout your workflows. Download the free whitepaper from Thermo Fisher Scientific. Cancer Progress 2022: Hear from Leading Oncology Innovators May 10-12, 2022 | Virtual Fierce Trial Master File Summit May 2-4, 2022 | New Orleans, LA & Streaming Live Fierce Leaders in Life Sciences Forum May 24, 2022 | Free Virtual Event Fierce Digital Pharma Engage June 14-15, 2022 | Huntington Beach, CA Fierce Digital Pharma Innovation Week June 21-23, 2022 | Virtual Event Fierce Biotech Next Gen June 29-30, 2022 | Free Virtual Event Fierce Pharma PR & Communications Summit East July 19-20, 2022 | Jersey City, NJ Fierce New Product Planning Summit September 20-22, 2022 | Boston, MA Fierce Digital Pharma East October 18-20, 2022 | Philadelphia, PA & October 25-28, 2022 | Virtual Event Fierce Pharma Meeting Professionals Summit November 2-3, 2022 | Atlantic City, NJ Fierce European Trial Master File Summit November 14-16, 2022 | London, UK Fierce Launch Readiness for Medical Affairs & Communications Teams Summit November 30-December 1, 2022 | Virtual Event Fierce JPM Week 2023 January 2023 | San Francisco, CA & Virtual | 